Skip to main content
Toggle navigation
Login
Home
Full Schedule
Home
Full Schedule
All Days
Thu, Sep 21
Fri, Sep 22
Sat, Sep 23
Full Schedule
Type here to filter the list
Thursday, September 21, 2023
8:00 AM - 8:15 AM
ET
Welcome
8:00 AM - 8:15 AM
ET
Welcome
Co-Chair:
Edward B. Garon, MD, MS
– University of California, Los Angeles
Co-Chair:
Corey J. Langer, MD, FACP
– Abramson Cancer Center, Hospital of the University of Pennsylvania
8:15 AM - 9:00 AM
ET
Session 1: Birdseye View of the Current Tretatment Landscape in Metastatic NSCLC without Actionable Mutations
8:15 AM - 9:00 AM
ET
Session 1: Birdseye View of the Current Tretatment Landscape in Metastatic NSCLC without Actionable Mutations
Presenter:
Karen Reckamp, MD
– Cedars Sinai Medical Center
9:00 AM - 9:45 AM
ET
Session 2: Sensitizing and Atypical EGFR Mutations
Presenter:
Gregory J. Riely, MD, PhD
– Memorial Sloan Kettering Cancer Center
9:00 AM - 9:45 AM
ET
Session 2: Sensitizing and Atypical EGFR Mutations
Presenter:
Gregory J. Riely, MD, PhD
– Memorial Sloan Kettering Cancer Center
9:45 AM - 9:50 AM
ET
Exhibit Hall
9:45 AM - 9:50 AM
ET
Break
9:50 AM - 10:50 AM
ET
Non-CME Innovation Theater
9:50 AM - 10:50 AM
ET
Non-CME Innovation Theater - Sponsored by AstraZeneca
10:50 AM - 11:00 AM
ET
Exhibit Hall
10:50 AM - 11:00 AM
ET
Exhibit Hall
11:00 AM - 11:45 AM
ET
Session 3: EGFR: The Challenge of Primary and Secondary Resistance
11:00 AM - 11:45 AM
ET
Session 3: EGFR: The Challenge of Primary and Secondary Resistance
Presenter:
Helena Yu, MD
– Memorial Sloan Kettering Cancer Center
11:45 AM - 12:00 PM
ET
Session 4: Debate: Alectinib vs Lorlatinib in ALK Positive
11:45 AM - 12:00 PM
ET
Session 4: Debate: Alectinib vs Lorlatinib in ALK Positive - Lorlatinib
Debate Speaker:
Misako Nagasaka, MD, PhD
– University of California Irvine
12:00 PM - 12:15 PM
ET
Session 4: Debate: Alectinib vs Lorlatinib in ALK Positive
12:00 PM - 12:15 PM
ET
Session 4: Debate: Alectinib vs Lorlatinib in ALK Positive - Alectinib
Debate Speaker:
Ticiana Leal, MD
– Emory University
12:15 PM - 12:30 PM
ET
Session 4: Debate: Alectinib vs Lorlatinib in ALK Positive
12:15 PM - 12:30 PM
ET
Q&A Panel
Panelist:
Ticiana Leal, MD
– Emory University
Panelist:
Misako Nagasaka, MD, PhD
– University of California Irvine
12:30 PM - 12:35 PM
ET
Exhibit Hall
12:30 PM - 12:35 PM
ET
Break
12:35 PM - 1:35 PM
ET
Non-CME Innovation Theater
12:35 PM - 1:35 PM
ET
Non-CME Innovation Theater - Sponsored by Sanofi
1:35 PM - 2:20 PM
ET
Session 5: Special Topic – Unique Immune Combinations with CPIs
1:35 PM - 2:20 PM
ET
Session 5: Unique Immune Combinations with CPIs
Presenter:
Hossein Borghaei, DO, MS
– Fox Chase Cancer Center
2:20 PM - 3:05 PM
ET
Session 6: Advancing the Management of NSCLC: A Focus on Emerging Therapies
2:20 PM - 3:05 PM
ET
Session 6: Advancing the Management of NSCLC: A Focus on Emerging Therapies
Presenter:
Ticiana Leal, MD
– Emory University
3:05 PM - 3:35 PM
ET
Exhibit Hall
3:05 PM - 3:35 PM
ET
Exhibit Hall
3:35 PM - 4:20 PM
ET
Session 7: The Era of ADCs in the Treatment of NSCLC Part 1: Class Overview and Specifics of TROP2, HER3, c-MET, and CEACAM5 Investigational ADCs
3:35 PM - 4:20 PM
ET
Session 7: The Era of ADCs in the Treatment of NSCLC Part 1: Class Overview and Specifics of TROP2, HER3, c-MET, and CEACAM5 Investigational ADCs
Presenter:
Barbara Melosky, MD
– Bc Cancer
4:20 PM - 5:05 PM
ET
Session 8: HER2 and the Emerging Roles of HER Family ADCs
4:20 PM - 5:05 PM
ET
Session 8: HER2 and the Emerging Roles of HER Family ADCs
Presenter:
Helen J. Ross, MD
– Rush University
